Absci Corporation
$3.95
▼
-2.86%
2026-04-21 05:01:01
www.absci.com
NMS: ABSI
Explore Absci Corporation stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$547.82 M
Current Price
$3.95
52W High / Low
$5.23 / $2.24
Stock P/E
—
Book Value
$1.25
Dividend Yield
—
ROCE
-64.8%
ROE
-62.5%
Face Value
—
EPS
$-0.84
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
140
Beta
2.01
Debt / Equity
2.8
Current Ratio
6.57
Quick Ratio
6.57
Forward P/E
-4.75
Price / Sales
162.86
Enterprise Value
$317.01 M
EV / EBITDA
-2.81
EV / Revenue
113.22
Rating
Strong Buy
Target Price
$8.03
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Entrada Therapeutics, Inc. | $13.56 | — | $535.6 M | — | -44.74% | -39.13% | $14.49 / $4.93 | $8.5 |
| 2. | Atea Pharmaceuticals, Inc. | $5.71 | — | $457.32 M | — | -65.67% | -44.34% | $6.45 / $2.46 | $3.52 |
| 3. | Pliant Therapeutics, Inc. | $1.29 | — | $79.87 M | — | -74.87% | -61.55% | $1.95 / $1.09 | $2.95 |
| 4. | Ovid Therapeutics Inc. | $2.89 | — | $381.12 M | — | -29.75% | -17.51% | $3.1 / $0.27 | $1 |
| 5. | Replimune Group, Inc. | $2.07 | — | $170.93 M | — | -53.14% | -90.88% | $13.24 / $1.5 | $2.64 |
| 6. | Ensysce Biosciences, Inc. | $0.48 | — | $4.49 M | — | -355% | -3.25% | $4.85 / $0.31 | $0.7 |
| 7. | Orchestra BioMed Holdings, Inc. | $4.35 | — | $268.03 M | — | -52.8% | -1.09% | $5.42 / $2.2 | $0.94 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0.65 M | 0.38 M | 0.59 M | 1.18 M | 0.67 M | — |
| Operating Profit | -36.14 M | -30.15 M | -31.39 M | -27.73 M | -29.77 M | — |
| Net Profit | -29.56 M | -28.71 M | -30.57 M | -26.35 M | -28.98 M | — |
| EPS in Rs | -0.19 | -0.19 | -0.2 | -0.17 | -0.19 | -0.24 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 2.8 M | 4.53 M | 5.72 M | 5.75 M |
| Operating Profit | -125.42 M | -108.89 M | -94.18 M | -106.75 M |
| Net Profit | -115.18 M | -103.11 M | -110.57 M | -104.9 M |
| EPS in Rs | -0.75 | -0.67 | -0.72 | -0.69 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 216.3 M | 213.61 M | 217.3 M | 321.01 M |
| Total Liabilities | 26.85 M | 34.48 M | 41.12 M | 46.59 M |
| Equity | 189.45 M | 179.13 M | 176.18 M | 274.41 M |
| Current Assets | 149.57 M | 133.83 M | 120.58 M | 186.86 M |
| Current Liabilities | 22.77 M | 28.66 M | 29.56 M | 30.27 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -92.92 M | -72.4 M | -64.64 M | -81.34 M |
| Investing CF | -50.16 M | -41.58 M | 81.94 M | -126.98 M |
| Financing CF | 105.95 M | 82.53 M | -4.48 M | 5.24 M |
| Free CF | -94.03 M | -72.81 M | -65.5 M | -97.51 M |
| Capex | -1.11 M | -0.4 M | -0.86 M | -16.18 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -20.71% | -0.5% | — | — |
| Earnings Growth % | 6.75% | -5.4% | — | — |
| Profit Margin % | -2274.06% | -1933.65% | -1825.37% | — |
| Operating Margin % | -2401.59% | -1647.08% | -1857.49% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -1964.76% | -1669.41% | -1588.53% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.